Most Read Articles
Audrey Abella, 21 Dec 2020
In patients with recurrent pericarditis (RP), the interleukin (IL)-1α and IL-1β cytokine trap rilonacept significantly reduced the risk of recurrence, with rapid resolution of episodes, the RHAPSODY* trial has shown.
Elaine Soliven, 12 Dec 2020
Treatment with finerenone led to significantly reduced risk of cardiovascular (CV) events in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D), regardless of their CV disease (CVD) history, according to the FIDELIO-DKD* trial presented at AHA 2020.
Pearl Toh, 15 Dec 2020
Intravenous (IV) iron supplementation with ferric carboxymaltose (FCM) reduces the risk of subsequent hospitalization for heart failure (HF) in iron-deficient patients after an episode of acute HF, shows the AFFIRM-AHF trial presented at the AHA 2020 Meeting.
Roshini Claire Anthony, 21 Dec 2020

Patients with high cardiovascular (CV) risk who received a high-dose trivalent influenza vaccine over three influenza seasons did not have a lower risk of cardiopulmonary hospitalization or death compared with those who received a standard-dose quadrivalent vaccine, according to the INVESTED* trial presented at AHA 2020.

Anxiety, depression link to aortic stiffness suggests brain–gut–vascular axis in Crohn's disease

25 Sep 2020

The associations of anxiety, depression, and chronic inflammation with aortic pulse wave velocity (aPWV) and systolic blood pressure (SBP) indicate the first evidence of a brain–gut–vascular axis and new potential targets for treatment in patients with Crohn’s disease (CD), reveals a study.

The authors performed a mediation analysis to reveal the potential connection between anxiety, depression, and aortic stiffness in CD patients in this multicentre observational cross-sectional study. They analysed 86 consecutive patients with CD and 86 matched control individuals.

Partial least squares structural equations modelling was used to test the connections between anxiety, depression, disease duration, aPWV, and brachial and central SBP.

Anxiety (path coefficient, 0.220; p=0.01) and disease duration (path coefficient, 0.270; p=0.02) correlated with aPWV, which in turn was associated with brachial SBP (path coefficient, 0.184; p=0.03) in CD patients. Such connections were more robust in those with active disease.

Central SBP (indirect effect, 0.090; p=0.01; indirect-to-total effect ratio, 41 percent) partly mediated the association between anxiety and aPWV, as did sympathetic hyperactivity in a pilot substudy. In patients with CD, anxiety and depression were highly associated. Results were confirmed when anxiety was substituted by depression.

“Patients with CD have an increased aortic stiffness, a known cardiovascular risk factor,” the authors said. “Anxiety, a key factor of the brain--gut axis in patients with CD, is implicated in the pathogenesis and progression of the disease and is linked with aortic stiffening in other clinical settings.”

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Audrey Abella, 21 Dec 2020
In patients with recurrent pericarditis (RP), the interleukin (IL)-1α and IL-1β cytokine trap rilonacept significantly reduced the risk of recurrence, with rapid resolution of episodes, the RHAPSODY* trial has shown.
Elaine Soliven, 12 Dec 2020
Treatment with finerenone led to significantly reduced risk of cardiovascular (CV) events in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D), regardless of their CV disease (CVD) history, according to the FIDELIO-DKD* trial presented at AHA 2020.
Pearl Toh, 15 Dec 2020
Intravenous (IV) iron supplementation with ferric carboxymaltose (FCM) reduces the risk of subsequent hospitalization for heart failure (HF) in iron-deficient patients after an episode of acute HF, shows the AFFIRM-AHF trial presented at the AHA 2020 Meeting.
Roshini Claire Anthony, 21 Dec 2020

Patients with high cardiovascular (CV) risk who received a high-dose trivalent influenza vaccine over three influenza seasons did not have a lower risk of cardiopulmonary hospitalization or death compared with those who received a standard-dose quadrivalent vaccine, according to the INVESTED* trial presented at AHA 2020.